BioSpace News Archive

PLx Pharma Inc. announced that three stock-keeping units of VAZALORE, the first and only U.S. Food and Drug Administration approved liquid-filled aspirin capsules, will be available in nearly 8,000 CVS stores later this month.

CryoLife, Inc., a leading cardiac and vascular surgery company focused on aortic disease, announced that it will participate in two upcoming virtual investor conferences.

SCYNEXIS, Inc., a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, announced grants of stock options to five new employees to purchase an aggregate of 24,500 shares of SCYNEXIS common stock at a per share exercise price of $6.97, the closing trading price on July 30, 2021.

The demand form Health is on a rise, owing to surge in incidence of chronic diseases such as diabetes and cancer.

The Insight Partner’s dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

The Insight Partner’s dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

Sepsis is an unusual systemic reaction caused by the body’s response to an infection.

Cerecor Inc., a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for immunologic, immuno-oncologic and rare genetic disorders, announced recent business progress and second quarter 2021 financial results.

Semler Scientific, Inc., a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, reported financial results for the three and six months ended June 30, 2021.

INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world’s only in vivo culture system (IVC), INVOcell®, today announced the Company’s first Joint Venture INVO Center practice in the United States, based in Birmingham, Alabama, will officially open on August 9, 2021.